"Pharmacogenetics of NSAIDs: Using CYP2C9 Genotype to Guide Treatment"
Non-steroidal anti-inflammatory drugs (NSAIDs) are some of the most commonly used drugs worldwide, but have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. Several drugs in this class are metabolized by CYP2C9, and polymorphisms in this enzyme that alter NSAID clearance may affect safety. This talk will summarize evidence supporting the association between CYP2C9 polymorphisms and NSAID exposure and discuss the recently published CPIC guidelines for usingCYP2C9 genotype to guide NSAID therapy.
Copyright © 2020 the Pharmacogenomics Research Network. All Rights Reserved.